Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis.

Patient-derived organoids reveal widespread CFTR dysfunction in half of chronic pancreatitis cases, including those with wild-type CFTR, and respond to CFTR modulators.

• Why it matters: Chronic pancreatitis affects millions globally, yet effective treatments are limited, partly due to incomplete understanding of its molecular mechanisms and variability among patients.
• What they did: Researchers developed a platform of 37 patient-derived organoids from diverse CP cases, analyzing their molecular features and testing responses to CFTR-targeted therapies.
• The result: The study shows CFTR modulators can restore function and reduce inflammation in CP organoids, suggesting a promising, broadly applicable therapeutic approach for personalized treatment.